{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:51:36Z","timestamp":1793364696764,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ophtha.2020.07.060","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T21:35:33Z","timestamp":1596576933000},"page":"234-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":204,"title":["Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3618-3980","authenticated-orcid":false,"given":"Mali","family":"Okada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Finger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Eldem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. James","family":"Talks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceri","family":"Hirst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-7374","authenticated-orcid":false,"given":"Luciano","family":"Paladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2020.07.060_bib1","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2020.07.060_bib2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2020.07.060_bib3","first-page":"CD005139","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"3","author":"Solomon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ophtha.2020.07.060_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology","volume":"126","author":"Bakri","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.07.060_bib5","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Meta-analysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2020.07.060_bib6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2020.07.060_bib7","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.07.060_bib8","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.07.060_bib9","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.07.060_bib10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/13548506.2014.936886","article-title":"Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review","volume":"20","author":"Boyle","year":"2015","journal-title":"Psychol Health Med"},{"key":"10.1016\/j.ophtha.2020.07.060_bib11","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00417-016-3384-0","article-title":"Psychological impact of anti-VEGF treatments for wet macular degeneration-a review","volume":"254","author":"Senra","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib12","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"key":"10.1016\/j.ophtha.2020.07.060_bib13","first-page":"285","article-title":"The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers","volume":"34","author":"Hong","year":"2018","journal-title":"Educ Inf"},{"key":"10.1016\/j.ophtha.2020.07.060_bib14","series-title":"Adherence to Long-Term Therapies: Evidence for Action","author":"Anonymous","year":"2003"},{"key":"10.1016\/j.ophtha.2020.07.060_bib15","first-page":"925","article-title":"[Compliance of age related macular degeneration patients undergoing anti-VEGF therapy: analysis and suggestions for improvement]","volume":"113","author":"Heimes","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.07.060_bib16","first-page":"92","article-title":"Persistence to aflibercept therapy in wet AMD patients engaged with the Smartsight Support program","volume":"46","author":"Chang","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.5301\/EJO.2011.7430","article-title":"Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration","volume":"21","author":"Oishi","year":"2011","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000001494","article-title":"Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis","volume":"37","author":"Kim","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2020.07.060_bib19","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/OPTH.S92548","article-title":"Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey","volume":"9","author":"Varano","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib20","first-page":"7194927","article-title":"Neovascular age-related macular degeneration in the very old (>\/=90 years): epidemiology, adherence to treatment, and comparison of efficacy","volume":"2017","author":"Subhi","year":"2017","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib21","first-page":"1035","article-title":"Reasons for delayed and discontinued therapy in age-related macular degeneration","volume":"115","author":"Wintergerst","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.07.060_bib22","first-page":"88","article-title":"The influence of patient compliance with antiangiogenic therapy on its efficacy for neovascular age-related macular degeneration","volume":"130","author":"Bobykin","year":"2014","journal-title":"Vestn Oftalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4274\/tjo.28003","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration","volume":"47","author":"Polat","year":"2017","journal-title":"Turk J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/eye.2015.128","article-title":"Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab","volume":"29","author":"Massamba","year":"2015","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2020.07.060_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ceo.13085","article-title":"Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence","volume":"46","author":"Ozturk","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajo.2012.06.031","article-title":"Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment","volume":"155","author":"Kruger Falk","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000001681","article-title":"Treatment of neovascular age-related macular degeneration patients with vascular endothelial growth factor inhibitors in everyday\u00a0practice: identification of health care constraints in Germany\u2014the PONS study","volume":"38","author":"Ehlken","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2020.07.060_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OPTH.S151611","article-title":"Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients","volume":"12","author":"Ehlken","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/aos.13233","article-title":"Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections","volume":"95","author":"Rasmussen","year":"2017","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.ophtha.2020.07.060_bib31","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/IAE.0000000000000173","article-title":"Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration","volume":"34","author":"Vaze","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2020.07.060_bib32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/09286586.2017.1397701","article-title":"Risk factors for discontinuation of treatment for neovascular age-related macular degeneration","volume":"25","author":"Westborg","year":"2018","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib33","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jfo.2014.11.015","article-title":"Ranibizumab for exudative age-related macular degeneration: a five-year study of adherence to follow-up in a real-life setting","volume":"38","author":"Boulanger-Scemama","year":"2015","journal-title":"J\u00a0Fr Ophtalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib34","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00417-019-04414-y","article-title":"Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage","volume":"257","author":"Angermann","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ajo.2014.05.014","article-title":"Anti-VEGF treatment patterns for neovascular age-related macular degeneration among Medicare beneficiaries","volume":"158","author":"Lad","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib36","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ajo.2011.11.032","article-title":"Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 Medicare beneficiaries","volume":"153","author":"Curtis","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib37","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaophthalmol.2018.3578","article-title":"Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections","volume":"136","author":"Obeid","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamaophthalmol.2019.4577","article-title":"Association of visit adherence and visual acuity in patients with neovascular age-related macular degeneration: secondary analysis of the comparison of age-related macular degeneration treatment trial","volume":"138","author":"Ramakrishnan","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib39","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1590\/S0004-27492010000200009","article-title":"Causes of interruption of bevacizumab therapy in age-related macular degeneration","volume":"73","author":"Nunes","year":"2010","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib40","first-page":"1251","article-title":"Coping with wet age-related macular degeneration\u2014a study from Switzerland","volume":"230","author":"H\u00fcsler","year":"2013","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"10.1016\/j.ophtha.2020.07.060_bib41","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00417-012-2177-3","article-title":"Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life","volume":"251","author":"Droege","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13548506.2016.1274040","article-title":"Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration","volume":"23","author":"Boyle","year":"2018","journal-title":"Psychol Health Med"},{"key":"10.1016\/j.ophtha.2020.07.060_bib43","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/eye.2017.271","article-title":"Exploring factors predicting changes in patients\u2019 expectations and psychosocial issues during the course of treatment with intravitreal injections for wet age-related macular degeneration","volume":"32","author":"Sii","year":"2018","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2020.07.060_bib44","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jfo.2017.03.005","article-title":"[A \u201cfast track\u201d to improve management of neovascular age related macular degeneration]","volume":"40","author":"Krivosic","year":"2017","journal-title":"J\u00a0Fr Ophtalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189035","article-title":"The impact of different anti-vascular endothelial growth factor treatment regimens on reducing burden for caregivers and patients with wet age-related macular degeneration in a single-center real-world Japanese setting","volume":"12","author":"Hanemoto","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.ophtha.2020.07.060_bib46","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.2147\/OPTH.S185052","article-title":"The burden of neovascular age-related macular degeneration: a patient\u2019s perspective","volume":"12","author":"Spooner","year":"2018","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"10.1016\/j.ophtha.2020.07.060_bib47","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.2147\/OPTH.S120803","article-title":"Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment","volume":"10","author":"Iida","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00417-013-2412-6","article-title":"Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration\u2014monthly injections versus pro re nata","volume":"252","author":"Droege","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/bjophthalmol-2019-315717","article-title":"ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD)","author":"Liakopoulos","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.07.060_bib50","unstructured":"A Phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration (Archway). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03677934. Accessed June 28,\u00a02020."},{"key":"10.1016\/j.ophtha.2020.07.060_bib51","unstructured":"Extension Study for the Port Delivery System with Ranibizumab (Portal). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03683251. Accessed June 28,\u00a02020."},{"key":"10.1016\/j.ophtha.2020.07.060_bib52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13300-013-0034-y","article-title":"Adherence to therapies in patients with type 2 diabetes","volume":"4","author":"Garc\u00eda-P\u00e9rez","year":"2013","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ophtha.2020.07.060_bib53","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s13300-019-0590-x","article-title":"Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes","volume":"10","author":"Guerci","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ophtha.2020.07.060_bib54","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.ophtha.2009.06.022","article-title":"A\u00a0clinician\u2019s guide to the assessment and management of nonadherence in glaucoma","volume":"116","author":"Budenz","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.07.060_bib55","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.ophtha.2009.06.023","article-title":"Patient-centered communication to assess and enhance patient adherence to glaucoma medication","volume":"116","author":"Hahn","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.07.060_bib56","first-page":"4610129","article-title":"Treatment efficacy and compliance in patients with diabetic macular edema treated with ranibizumab in a real-life setting","volume":"2018","author":"Best","year":"2018","journal-title":"J\u00a0Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164202030748X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164202030748X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:09:37Z","timestamp":1758982177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016164202030748X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S016164202030748X"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.07.060","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.07.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}